AIN457 provided fast and significant comfort of symptoms in up to 81 percent of patients with psoriasis Novartis has announced excellent results from three Stage II trials showing that AIN457 produced an instant and significant improvement of symptoms in sufferers with moderate-to-severe plaque psoriasis. The results were offered at the annual European Academy of Dermatology and Venereology Congress, in Lisbon, Portugal. In a single study, 81 percent of individuals receiving AIN457 150mg subcutaneously once a month experienced at least a 75 percent improvement of psoriasis signs or symptoms as measured by PASI vs 9 percent for placebo at week 12 (p.Previously, the editor and editorial board of a journal knew both the scientific field it covered and the people working in it, but it’s extremely difficult to end up being sufficiently well connected when both editors and submissions come from all over the world. Having authors suggest the very best reviewers may seem just like a good idea therefore. In the aftermath of the recent scandals involving fake peer reviewers, many journals have decided to carefully turn off the reviewer-recommendation option on the manuscript-submission systems. But that move might not be enough, as the publisher Hindawi found out this past spring. Although Hindawi doesn’t let authors suggest reviewers for their manuscripts, it made a decision to examine the peer-review records for manuscripts submitted in 2013 and 2014 for possible fraud.